Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi’s acquisition of Vigil Neuroscience involves purchasing the company for $8 per share in cash, along with an additional $2 in contingent value rights, pending the commercial success of ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Foxconn Technology (OTCPK:FXCOF) is among potential bidders for UTAC Holdings in a transaction that could value the Singapore-based semiconductor assembly and testing company at about $3 billion.

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...

In its most recent quarter, Nvidia delivered blockbuster results, driven by full-scale production of its Blackwell GPUs and ...

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US ...